XRCC1 Inhibitors
The chemical class of XRCC1 inhibitors comprises a diverse range of compounds that indirectly modulate the activity of XRCC1 by targeting various DNA damage response pathways and cellular processes associated with its function. These inhibitors act through different mechanisms, influencing XRCC1 activity by altering the upstream or downstream signaling elements of the pathways in which XRCC1 is involved. Compounds like Camptothecin, Etoposide, and Cisplatin exemplify this class by targeting topoisomerases and inducing DNA crosslinking, respectively. These actions lead to increased DNA damages, indirectly inhibiting XRCC1 by overwhelming its repair capacity. Similarly, Mitomycin C and Bleomycin, by causing complex DNA damages, and PARP inhibitors, by reducing DNA single-strand break repair, indirectly challenge XRCC1's efficiency in DNA repair.
Other notable compounds in this class include ATR, ATM, CHK1, and DNA-PKcs inhibitors, which disrupt various aspects of the DNA damage response and repair mechanisms. By inhibiting these key components, these compounds can indirectly affect XRCC1's ability to effectively participate in DNA repair processes. In essence, the chemical class of XRCC1 inhibitors is characterized by compounds with diverse mechanisms of action, all converging on the modulation of DNA repair and response pathways. By either directly targeting upstream elements of DNA repair or indirectly influencing XRCC1 activity through pathway cross-talk and signaling interactions, these inhibitors demonstrate the interconnected nature of cellular DNA repair networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits topoisomerase I, disrupting DNA replication and repair processes. This inhibition could indirectly affect XRCC1 by increasing the demand for DNA repair, potentially overloading its repair capacity. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide, a topoisomerase II inhibitor, causes DNA strand breaks. This can indirectly inhibit XRCC1 by creating complex DNA damages that are challenging for XRCC1-mediated repair mechanisms. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C forms DNA crosslinks, hindering DNA replication and repair. Its action could stress XRCC1-dependent repair pathways, potentially inhibiting XRCC1 activity indirectly. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea inhibits ribonucleotide reductase, affecting DNA synthesis and repair. This inhibition can lead to DNA damage accumulation, indirectly challenging XRCC1-mediated repair processes. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin induces DNA crosslinking, which can indirectly inhibit XRCC1 by causing complex DNA damages that XRCC1 might struggle to repair efficiently. | ||||||
Bleomycin Sulfate | 9041-93-4 | sc-200134 sc-200134A sc-200134B sc-200134C | 10 mg 50 mg 100 mg 500 mg | $210.00 $624.00 $1040.00 $2913.00 | 38 | |
Bleomycin Sulfate causes DNA strand breaks and oxidative damage. This can indirectly affect XRCC1 by overwhelming its repair capacity with extensive DNA damage. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitors prevent DNA single-strand break repair. Their action can indirectly inhibit XRCC1 by increasing the load of unrepaired DNA damages that require XRCC1 intervention. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
ATR inhibitors disrupt DNA damage response pathways. By inhibiting ATR, these compounds can indirectly affect XRCC1's ability to respond to DNA damage effectively. | ||||||
ATM Kinase Inhibitor | 587871-26-9 | sc-202963 | 2 mg | $110.00 | 28 | |
ATM inhibitors impede the cellular response to DNA double-strand breaks. This inhibition can indirectly challenge XRCC1's role in DNA repair processes. | ||||||
SCH 900776 | 891494-63-6 | sc-364611 sc-364611A | 5 mg 10 mg | $255.00 $338.00 | ||
CHK1 inhibitors disrupt cell cycle checkpoints. By inhibiting CHK1, they can indirectly affect XRCC1 by increasing DNA damages that overwhelm XRCC1-mediated repair mechanisms. | ||||||